Shah Capital pushes Novavax sale, warns of proxy fight
By Sneha SK and Sriparna Roy (Reuters) -Shah Capital, Novavax’s second-largest shareholder, is pressing the biotech’s board to make strategic changes, including a possible sale, and warned it could launch a proxy fight if no progress is made in the next four months. In a second letter to Novavax’s board in less than a month,…